Factors associated with complex visual hallucinations during antidepressant treatment

Human Psychopharmacology

Volumn 19, Issue 8, 2004, Pages 577-584

  Cancelli, Iacopo ^a   Marcon, Gabriella ^a   Balestrieri, Matteo ^a,b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Acetylcholine; Antidepressant; Review; Serotonin; SSRI; Visual hallucinations

Indexed keywords

ACETYLCHOLINE; AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LEVODOPA; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PHENELZINE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; AUDITORY HALLUCINATION; BIPOLAR DISORDER; CLINICAL TRIAL; CONSCIOUSNESS; DEMENTIA; DEPRESSION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SENSITIVITY; HUMAN; HYPNAGOGIC HALLUCINATION; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VISUAL HALLUCINATION;

ACETYLCHOLINE; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HALLUCINATIONS; HUMANS; MONOAMINE OXIDASE INHIBITORS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 11144337203     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.640     Document Type: Review

References (52)

1. Achamallah NS. 1992 Visual hallucinations after combining fluoxetine and dextromethorphan. Am J Psychiatry 149: 140.
2. Aghajanian GK, Marek GJ. 1999. Serotonin and hallucinogens. Neuropsychopharmacology 21(Suppl. 2):16S-23S.
3. AHFS Drugs Information. 2004. American Society of Health-System Pharmacists: Bethesda.
4. Ames D, Wirshing WC, Szuba MP. 1992. Organic mental disorders associated with bupropion in three patients. J Clin Psychiatry 53: 53-55.
5. Anghelescu I, Klawe C, Himmerich H, Szegedi A. 2001. Topiramate in venlafaxine-induced visual hallucinations in an obese patient with a posterior cerebral artery infarction. J Clin Psychopharmacol 21: 462-464.
6. Asaad G, Shapiro B. 1986. Hallucinations: theoretical and clinical overview. Am J Psychiatry 143: 1088-1097.
7. Barnes FF. 1982. Precipitation of mania and visual hallucinations by amoxapine hydrochloride. Compr Psychiatry 23 590-592.
8. Bazire S. 2004. Psychotropic Drug Directory 2003/04. Fivepin Publishing: Salisbury, UK.
9. Bender MB, Feldman M, Sobin AJ. 1968. Palinopsia. Brain 91: 321-338.
10. Biswas PN, Wilton LV, Shakir SA. 2003. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13 554 patients in England. J Psychopharmacol 17: 121-126.
11. Bourgeois JA, Thomas D, Jhoansen T, Walker DM. 1998. Visual hallucination associated with fluoxetine and sertraline. J Clin Psychopharmacol 18: 482-483.
12. Cameron DE. 1959. The use of tofranil in the aged. Can Psychiatr Assoc J 4(Suppl.):160-165.
13. Delay J, Deniker P. 1959. Efficacy of tofranil in the treatment of various types of depression: a comparison with other antidepressant drugs. Can Psychiatr Assoc J 4(Suppl.): 100-112.
14. Dukes MN. 1990. The importance of adverse reactit in drug regulation. Drug Saf 5: 3-6.
15. Elko C, Burgess J, Robertson W. 1998. Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J Toxicol Clin Toxicol 36: 195-203.
16. Filteau MJ, Leblanc J, Lefrancoise S, Demers MF. 2000. Visual and auditory hallucinations with association of bupropion and valproate. Can J Psychiatry 45: 198-199.
17. Freijzer PL, Brenninkmeijer JH. 2002. Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation. Ned Tijdschr Geneeskd 146: 574-575.
18. Galynker I, Kampf R, Rosenthal R. 1994. Dose related visual hallucinations in macular degeneration patients receiving phenelzine. Am J Psychiatry 151: 450.
19. Glennon RA, Titeler M, McKenney JD. 1984. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35: 2505-2511.
20. Greenberg WM. 1999. Visual field shimmering associated with nefazodone. J Clin Psychiatry 60: 124-125.
21. Hanson LC, Punell NG. 1961. Treatment of depressive states in old age with imipramine. Nervenarzt 32: 22-25.
22. Hemmingsen R, Rafaelsen OJ. 1980. Hypnagogic and hypnopompic hallucinations during amitriptyline treatment. Acta Psychiatr Scand 62: 364-368.
23. Holmes C, Arranz MJ, Powell JF, Collier DA, Lovestone S. 1998. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet 7: 1507-1509.
24. Hori H, Terao T, Nakamura J. 2000. Visual perseveration: a new side effect of maprotiline. Acta Psychiatrica Scand 101: 476-477.
25. Hudgens RW, Tanna VL, Harley JD, Learly DJ. 1966. Visual hallucinations with iminodibenzyl antidepressants. JAMA 198: 199-200.
26. Hughes MS, Lessell S. 1990. Trazodone induced palinopsia. Arch Ophthalmol 108: 399-400.
27. Kane FJ Jr, Keeler MH. 1964. Visual hallucinosis while receiving imipramine. Am J Psychiatry 121: 611-612.
28. Kavasaki A, Purvin V. 1996. Persistent palinopsia following ingestion of lysergic acid diethylamide. Arch Ophthalmol 114: 47-50.
29. Klein DF. 1965. Visual hallucinations with imipramine. Am J Psychiatry 121: 911-914.
30. Kraus RP. 1996. Visual 'trails' with nefazodone therapy. Am J Psychiatry 153: 1365-1366.
31. Kumagai R, Ohnuma T, Nagata T, Arai H. 2003. Visual and auditory hallucinations with excessive intake of paroxetine. Psychiatry Clin Neurosci 57: 548-549.
32. Lauterbach EC. 1993. Dopaminergic hallucinosis with fluoxetine in Parkinson's disease. Am J Psychiatry 150: 1750.
33. Lehmann HE, Cahn CH, de Verteuil R. 1958. The treatment of depressive conditions with imipramine. Can Psychiatr Assoc J 3 155-164.
34. Mackay FJ, Pearce GL, Freemantle SN, Mann RD. 1999. Nefazodone in community use: the results of prescription-event monitoring. Pharmacoepidemiol Drug Safe 8: 267-273
35. Manford M, Andermann F. 1998. Complex visual hallucinations. Clinical and neurobiological insights. Brain 121: 1819-1840.
36. Marcon G, Cancelli I, Zamarnian L, Bergonzi P, Balestrieri M. 2004. Visual hallucinations with sertraline. J Clin Psychiatry 65: 446-447.
37. Nestler EJ, Hyman SE, Malenka RC. 2001. Higher cognitive function and psychosis. In Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, Nestler EJ, Hyman SE, Malenka RC (eds). McGraw-Hill: New York; 383-408.
38. Norman TR, Judd F, Holwill BJ, Burrows GD. 1982. Doxepin and visual hallucinations. Aust N Z J Psychiatry 16: 295-296.
39. Omar SJ, Robinson D, Davies HD, Miller TP, Tinklenberg JR. 1995. Fluoxetine and visual hallucinations in dementia. Biol Psychiatry 38: 556-558.
40. Pelak VS, Liu GT. 2004. Visual hallucinations. Curr Treat Options Neurol 6: 75-83.
41. Perry E, Walker M, Grace J, Perry R. 1999. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 22: 273-280.
42. Perry EK, McKeith I, Thompson P, et al. 1991. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci 640: 197-202.
43. Rabey JM, Orlov E, Korczyn AD. 1996. Comparison of fluvoxamine versus amitriptyline for the treatment of depression in Parkinson's disease. Neurology 46: A 374.
44. Rosebraugh C, Flockhart D, Yasuda S, et al. 2000. Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. J Clin Pharmacol 41: 224-271.
45. Rundell JR, Murray GB. 1988. Visual hallucinations on low dose amitriptyline. J Clin Psychopharmacol 8: 75-76.
46. Schlauch R. 1979. Hypnopompic hallucinations and treatment with imipramine. Am J Psychiatry 136: 219-220.
47. Schuld A, Archelos J, Friess E. 2000. Visual hallucination and psychotic symptoms during treatment with selective serotonin reuptake inhibitors: is the sigma receptor involved? J Clin Psychopharmacol 20: 579-580.
48. Sharpley AL, Cowen PJ. 1995. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 37: 85-98.
49. Spigset O. 1999. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 20: 277-287.
50. Stoller A. 1960. Tofranil a new antidepressant drug. Med J Aust 47: 412-414.
51. Terao T, Ohmori O, Shinkai T. 1999. A puzzling case of seizures and visual hallucinations during clomipramine treatment with a high dose but causing a low serum concentration. Acta Psychiatr Scand 99: 388-390.
52. Van Puijenbroek EP, Egberts AC, Krom HJ. 1996. Visual hallucinations and amnesia associated with the use of zolpidem. Int J Clin Pharmacol Ther 34: 318.